# Afamelanotide

Canonical source: https://retacompare.com/encyclopedia/afamelanotide

Selective MC1R-preferring agonist; stimulates eumelanin synthesis in melanocytes, providing photoprotection.

Reference facts

Also known asMelanotan I, Scenesse, [Nle⁴, D-Phe⁷]-α-MSHCategorySexual Health & MSHMechanism of actionSelective MC1R-preferring agonist; stimulates eumelanin synthesis in melanocytes, providing photoprotection.TargetsMC1RIndications under research or approvedErythropoietic Protoporphyria (EPP), Adult variegate porphyria (orphan)Regulatory status (reference entry)FDA-approved (2019, Scenesse implant)Half-life~30 minutes (formulated as long-acting subcutaneous implant)Sequence notesLinear analog Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2; 13 residues.Molecular weight (Da)1647Originator / sponsorClinuvel PharmaceuticalsFirst reported1980
    Primary References

Langendonk et al., NEJM 2015 (Afamelanotide EPP)


    Explore research articles about Afamelanotide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Langendonk et al., NEJM 2015 (Afamelanotide EPP): https://www.nejm.org/doi/full/10.1056/NEJMoa1411481